Bilayer Gastroretentive Modified-Release Tablets: A Quality-by-Design Approach to Achieving Precise Drug Release and Prolonged Gastric Retention

Introduction

Oral solid dosage forms remain the most widely adopted drug delivery systems due to their convenience, stability, and patient compliance. However, for drugs with site-specific absorption in the upper gastrointestinal (GI) tract, rapid gastric emptying often limits bioavailability.

To address this challenge, bilayer gastroretentive modified-release (GR-MR) tablets have emerged as a sophisticated formulation strategy. By integrating an immediate-release (IR) layer for rapid onset and a gastroretentive extended-release (GR-ER) layer for prolonged gastric residence, this system enables both precise release kinetics and enhanced in vivo exposure.

This white paper addresses a critical and often overlooked aspect of product development by applying a Quality-by-Design (QbD) framework to design and control product quality.

Figure 1: Bilayer tablets

Gastroretentive Technologies: Mechanism Overview

Gastroretentive drug delivery systems (GRDDS) can be broadly categorized as follows:

Table 1. Overview of GRDDS Technologies: mechanisms, advantages and limitations

Among these, swelling systems are most commonly used in bilayer designs due to their balance of feasibility and performance.

Bilayer GR-MR Systems: A System-Level Advantage

Table 2. Comparison of different oral drug delivery systems

This bilayer design is particularly valuable for:

· Narrow absorption window drugs

· Molecules with solubility-limited absorption

· Therapies requiring rapid onset + sustained exposure

Figure 2: Mechanisms of Action of Various Gastroretentive Tablets

Quality by Design for a Bilayer GR-MR

1. Quality Challenges: Where Complexity Emerges

Bilayer GR tablets introduce multi-dimensional quality risks:

Structural risks

· Interlayer adhesion failure

· Delamination during handling or dissolution

Performance risks

· Uncontrolled swelling or erosion

· Inconsistent retention behavior

· Dual-release profile variability

Manufacturing risks

· Compression sequence sensitivity

· Layer weight variation

· Polymer hydration kinetics

These complexities make QbD not optional—but essential.

2. QTPP → CQAs: Translating Clinical Goals into Quality Targets

Quality Target Product Profile (QTPP)

· Rapid onset (IR layer)

· Controlled release (8–24 h)

· Reliable gastric retention

· Mechanical robustness during swelling

· Stable performance across shelf life

These translate into the following Critical Quality Attributes (CQAs).

3. Critical Quality Attributes (CQAs)

(1) Bilayer Integrity & Mechanical Strength

· Adhesion strength between layers

· Tablet hardness / friability

· Resistance to delamination

Crystal Pharmatech incorporate compaction simulation to provide comprehensive mechanical properties for both layer composition powders and implement a special testing device to measure layer-layer bonding strength to guide bilayer tablet formulation development.

Figure 3: STYL′One Compaction Simulator

(2) Swelling & Matrix Expansion Behavior

Driven by hydrophilic polymers (e.g., HPMC, PEO):

· Swelling index

· Matrix integrity

· Expansion kinetics

Mature in-vitro swelling index evaluation methodology in CP

(3) Layer-Specific Dissolution

· IR+ER dose combination design strategy by PBPK modeling

· IR: rapid release (e.g, >80% in ~30 min)

· ER: controlled release over hours

4. Critical Material Attributes (CMAs)

Polymer-related

· HPMC viscosity grade

· PEO molecular weight

· Hydration rate

API-related

· Particle size

· Solubility / pKa

· Solid-state form

M3(Material+Molecule+Medicine) philosophy to fully understand the material and molecule physiochemical properties to select the desired excipients for formulation composition.

5. Critical Process Parameters (CPPs)

Compression process

· First-layer pre-compression force

· Main compression force

· dwell time

Layer control

· Weight ratio (IR vs ER)

Granulation

· Binder level

· Residual moisture

Using advanced compaction simulations to predict mechanical behavior, layer adhesion, and compression profiles, etc. Reduces trial-and-error, and accelerates development of robust, high-quality oral dosage forms.

All CPPs should be mapped to CQAs via DoE-based design space.

6. Dissolution & In Vitro Performance Testing

Dissolution is the core quality control tool:

Method design

· Medium: simulated gastric fluid (pH 1.2)

· Duration: up to 24 h

· Apparatus: paddle (USP II)

Advanced characterization

· Swelling kinetics

· Matrix imaging

Figure 4: PK data and in vitro dissolution of gastric-retentive bilayer sustainedrelease tablets (simulated curves from GastroPlus)

7. Stability

Key degradation risks

Table 3. Degradation mechanisms and corresponding mitigation strategies

8. A Practical QbD Framework

A robust development strategy typically follows:

1. Define QTPP

2. Identify CQAs

3. Link CMAs & CPPs via risk assessment

4. Apply DoE to establish design space

5. Develop discriminatory dissolution methods

6. Confirm robustness via stability + scale-up

Conclusion

Developing bilayer gastroretentive MR tablets is far more than combining two functional layers. It requires:

· Deep understanding of material science

· Precise control of process parameters

· Systematic application of QbD principles

When executed effectively, this platform enables:
✔ Precise release control
✔ Prolonged gastric retention
✔ Enhanced bioavailability for challenging molecules

About Crystal Pharmatech

Crystal Pharmatech, founded in 2010, is a global contract research organization with approximately 300 employees and four R&D centers in New Jersey (USA), San Francisco (USA), Toronto (Canada), and Suzhou (China). Collectively, these sites provide integrated support for pharmaceutical and biotechnology companies worldwide. Our capabilities span three specialized platforms: in small molecules, we offer API solid state research and crystallization, preformulation, formulation development, and GMP manufacturing and supply; under Crystal Bio Solutions, we deliver bioanalytical and biomarker testing, biologics characterization and CMC analytics, and clinical pharmacology; and through Crystal NAX (Nucleic Acid Excellence), we provide end-toend solutions for nucleic acid therapeutics, from early research through clinical development.

References

[1] Khar,R.K., Vyas,S.P.,Ahmad,F.J.,& Jain,G.K.(2013).Gastroretentive Drug Delivery Systems.CRC Press.https://doi.org/10.1201/b14636

[2] Singh,B.N.,& Kim,K.H.(2000).Gastroretentive drug delivery systems:An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release,63(3),235-259.https://doi.org/10.1016/S0168-3659(99)00204-7

[3] Arora,S., Ali,J.,Ahuja,A.,Khar,R.K.,& Baboota,S.(2005).Floating drug delivery systems: A review.AAPS PharmSciTech,6(3),E372-E390. https://doi.org/10.1208/pt060347

[4] Talukder,R.,& Fassihi,R.(2004). Gastroretentive delivery systems: A mini-review.Drug Development and Industrial Pharmacy,30(10),1019-1028. https://doi.org/10.1081/DDC-200033481

[5] Bardonnet,P.L.,Faivre,V.,Piffaretti,J.C.,& Falson,F.(2006). Gastroretentive dosage forms: Overview and special case of helicobacter pylori.International Journal of Pharmaceutics, 277(1-2),1-13. https://doi.org/10.1016/j.ijpharm.2005.12.029

[6] Streubel,A., Siepmann,J.,& Bodmeier,R.(2003). Floating matrix tablets based on low density foam powder: Effects of formulation and processing parameters on drug release. European Journal of Pharmaceutics and Biopharmaceutics,55(3),329-335.https://doi.org/10.1016/S0939-6411(02)00171-2

[7] Prajapati, V.B.,Jani,G.K.,Moradiya,N.G.,& Randeria,N.P.(2015).Gastroretentive drug delivery systems: A review. International Pharmaceutical Investigation,5(3),147-157.https://doi.org/10.4103/2230-973X.160848

[8] Chen,R.N.,Ho,H.O.,&Sheu,M.T.(1999). Characterization of captopril microparticle preparations and the determination of their transport across intestinal epithelial cells. International Journal of Pharmaceutics, 184(2), 161-170.https://doi.org/10.1016/S0378-5173(99)00094-2

[9] Klausner, E. A., Lavy, E., Friedman, M.,& Hoffman, A.(2003).gastroretentive dosage forms. Journal of Controlled Release, 90(2), 143-162.gastroretentive dosage forms. Journal of Controlled Release, 90(2), 143-162.https://doi.org/10.1016/S0168-3659(03)00139-7

[10] Wen, H.,& Park, K.(Eds.).(2010). Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. Wiley.https://doi.org/10.1002/9780470537240